ARUNA REPORTS COMMERCIAL DEBUT OF MESENCHYMAL CELLS.ArunA Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. , Inc., Athens. Geo., will make its CELL-EZ(TM) brand hMC(TM) human mesenchymal progenitor cells commercially available to the research community in mid 2009. Derived from pluripotent plu·rip·o·tent or plu·ri·po·ten·tial adj. 1. Capable of affecting more than one organ or tissue. 2. Not fixed as to potential development. Used of an embryonic cell. human embryonic stem cells, ArunA's hMC lines will offer unique, highly proliferative uniform populations of mesenchymal cells in a feeder free monolayer mon·o·lay·er n. 1. A film or layer one molecule thick formed at the interface between water and either oil or air by a substance such as a partially esterified fatty acid that contains both hydrophobic and hydrophilic groups in the same culture. The introduction of our CELL-EZ hMC(TM) cell lines is a significant step forward for stem cell research." Dr. Steven Stice, ArunA CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. and Co-Founder commented, "CELL-EZ hMC(TM) will provide a human cell based format for a wide range of research in areas from osteogenisis to cancer research. Unlike human bone marrow and other tissue derived mesenchymal cells, ArunA's hMC cells have the unique ability to differentiate into osteoblasts Osteoblasts Cells in the body that build new bone tissue. Mentioned in: Bone Grafting, Osteoporosis and chondrocytes but not adipocytes, making them a unique tool for research and drug discovery directed at areas such as Osteoporosis." The CELL-EZ hMC(TM) cell lines were further developed by ArunA through a technology license agreement with the University of Georgia Organization The President of the University of Georgia (as of 2007, Michael F. Adams) is the head administrator and is appointed and overseen by the Georgia Board of Regents. using a proprietary platform technology for producing progenitor cells from pluripotent stem cells. The CELL-EZ hMC(TM) cell lines are from a stable genetic background and can be genetically modified to produce constant and more informative research results. This product line compliments ArunA's portfolio of pluripotent stem cell products derived from human embryonic stem cells. About ArunA Biomedical Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity neurotoxicity /neu·ro·tox·ic·i·ty/ (noor?o-tok-sis´it-e) the quality of exerting a destructive or poisonous effect upon nerve tissue. and breakthroughs in understanding human development and diseases such as Parkinson's, Alzheimer's, Huntington's and cancer. For more information, visit http://www.ArunAbiomedical.com or call 706/542-9191. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion